Imipramin Neuraxpharm

Imipramine Hydrochloride, the active ingredient in Imipramin Neuraxpharm, is a tricyclic antidepressant presented as an oral tablet for oral use. It is prescribed for the treatment of depressive disorders and related conditions in adult patients.

GNH USA supplies Imipramin Neuraxpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imipramin Neuraxpharm, a tricyclic antidepressant, is used in several psychiatric and urological conditions. - Depression: alleviates depressive symptoms and improves mood in major depressive disorder. - Panic disorder: reduces the frequency and intensity of panic attacks. - Nocturnal enuresis (children): decreases nighttime urinary episodes in pediatric patients.

Imipramin Neuraxpharm may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Dry mouth: reduced salivation leading to discomfort. - Constipation: slowed gastrointestinal motility. - Drowsiness: increased sedation, especially after initiation. - Weight gain: gradual increase in body weight.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening. - Seizures: risk of convulsive episodes, particularly in predisposed individuals. - Severe hypotension: marked drop in blood pressure causing dizziness or fainting.

Before prescribing Imipramin Neuraxpharm, clinicians should consider several safety measures. - Cardiovascular assessment: evaluate heart disease history due to arrhythmia risk. - Suicidal ideation monitoring: watch for worsening mood, especially early in treatment. - Elderly caution: increased sensitivity to anticholinergic effects. - Discontinuation: avoid abrupt cessation to prevent withdrawal symptoms. - Recent myocardial infarction: contraindicated in patients with recent heart attack. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Imipramin Neuraxpharm can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: potential serotonin syndrome. - CYP2D6 inhibitors (e.g., fluoxetine): increased imipramine plasma levels.

Moderate Interactions (Monitor Closely): - Antihistamines or anticholinergics: additive anticholinergic burden. - CNS depressants (e.g., benzodiazepines, alcohol): enhanced sedation and respiratory depression.